Detalles de la búsqueda
1.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 390(4): 301-313, 2024 Jan 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38084760
2.
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
Blood
; 143(7): 592-596, 2024 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38048557
3.
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Lancet Oncol
; 24(1): 64-76, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36528035
4.
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity.
Blood
; 138(18): 1705-1720, 2021 11 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34077955
5.
Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis.
Haematologica
; 108(3): 833-842, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36200419
6.
COVID-19 does not impact on outcome of myeloma patients infected while undergoing autologous stem cell transplantation.
Hematol Oncol
; 41(3): 555-558, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36786526
7.
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Hematol Oncol
; 40(4): 704-715, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35608183
8.
The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation.
Ann Hematol
; 101(6): 1227-1237, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35380239
9.
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 22(12): 1705-1720, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34774221
10.
Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19.
Cancer
; 126(23): 5069-5076, 2020 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32910456
11.
Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years.
Am J Hematol
; 95(7): 759-765, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32242970
12.
Predictive role of sustained imaging MRD negativity assessed by diffusion-weighted whole-body MRI in multiple myeloma.
Am J Hematol
; 98(9): E230-E232, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37317959
13.
Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing.
Curr Osteoporos Rep
; 15(5): 499-506, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28889371
14.
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials.
Haematologica
; 106(1): 291-294, 2021 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32107338
15.
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study.
Leuk Lymphoma
; 65(6): 833-842, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38497533
16.
Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in Italy.
EJHaem
; 5(3): 485-493, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38895069
17.
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells.
Blood Cancer J
; 14(1): 94, 2024 Jun 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38849344
18.
A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.
Cancer Med
; 13(7): e7071, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38558233
19.
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing.
EClinicalMedicine
; 60: 102016, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37396800
20.
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial.
EClinicalMedicine
; 60: 102017, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37396807